Maretak bij kanker, Iscador
Doordat ik veel sites bezoek loop ik
steeds weer tegen zaken aan die bij mij ook onbekend waren. Het gaat om met name
natuurlijke oplossingen voor ziektes zoals kanker. Waarom lees ik dit niet in de media?
Heel simpel, de kranten weigeren aandacht te besteden aan dit soort zaken en willen het
volk dus dom houden over alternatieven voor reguliere behandelmethodes.
Ik kan echt kwaad worden om dit soort zelfcensuur, de journalisten bepalen dus wat goed
voor ons is om te weten. De heksenjacht van de anti kwakzalver club wordt medegesteund
door volgelingen onder journalisten dus bent u aangewezen op alternatieve tijdschriften en
internet want de media vindt dit soort zaken blijkbaar niet interessant en loopt liever de
introduktie feestjes af van nieuwe medicijnen. Maar goed, ik kan die wereld niet
veranderen en er zullen hopelijk journalisten opstaan die echt onderzoek willen gaan doen
naar oplossingen als Iscador, Ukrain etc etc.
Ondertussen ga ik door op kleinere schaal
en geef u wel de informatie over zowel reguliere als alternatieve mogelijkheden. Laat u
nooit afbluffen door vaktermen, verbreedt je kennis zodat je betere keuzes kunt maken en
alle voordelen en nadelen van behandelmethodes kunt afwegen.
Nederland loopt flink achter op andere
landen waar wel serieus naar alternatieve methodes wordt gekeken. In het calvinistische
Nederland is de patiënt helaas nog aangewezen op een kleine groep artsen die breder
willen kijken en de oorzaak van de ziekte willen aanpakken en niet alleen de symptomen.
Men heeft via de rechter geprobeerd het
middel Iscador van de markt te krijgen maar tot in hoger beroep heeft de rechter de
minister in het ongelijk gesteld en mag het dus worden voorgeschreven door antroposofische
artsen.
Ron
Werking Iscador
Uit wetenschappelijk onderzoek (*) komen
aanwijzingen dat Iscador de volgende werkingen heeft:
- Het middel bevat stoffen die de celdeling
van tumoren kunnen afremmen of deze cellen doen sterven. (9-11a)
- Het activeert het immuunsysteem, waardoor
onze lichamelijke afweer toeneemt. (1, 13-15, 16, 17)
- Het doet de zelfregulatie toenemen.
Hiermee wordt bedoeld: het vermogen om het leven meer in eigen hand te nemen. Het gevolg
hiervan is onder andere een verhoogd gevoel van welbevinden en meer zekerheid. (1-7, 12,
12a)
- Iscador stimuleert de aanpak van pijn
onderdrukkende stoffen in het eigen lichaam en kan daardoor pijnstillend werken. (1-3, 6,
8)
- Indien tijdig gestart (vóór de operatie
of tijdens de bestraling en/of de chemotherapie) leidt de Iscador-behandeling tot een
beter en sneller herstel van deze ingrepen. De ontwikkeling van recidiven en metastasen
wordt geremd en de bijwerkingen verminderen. (9-11a, 18)
Meer info: http://www.weleda.nl/d_geneesmiddelen/kanker_en_iscador.htm
(*) Studies
1 Hajto et al, Deutsche Onkologie
1991/23/1, p. 1-6.
2 Wagner, Prakische Prüfungsmethoden zur
Beurteilung der Misteltherapie, Urachhaus, Stuttgart 1994.
3 Wagner, Iscador M/Qu spezial, Urachhaus
Stuttgart 2001.
4 Grossarth-Maticek et al, Alternative
Therapies 2001/7/3, p. 57-78
5 Borelli, La Medicina Biologica 1999, p.
27-30.
6 Hassauer et al, Onkologie 2 1979/1, p.
28-36.
7 U. Dold et al, Krebszusatztherapie beim
nicht-kleinzelligen Bronchial- karzinom, Thieme Verlag, Stuttgart 1991.
8 Leroi, Ärztliche Praxis 1983/35/19, p.
482-87.
9 Ribéreau-Gayon et al, Experientia
1986/42, p. 594-99.
10 Kuttan et al, Cancer Letters 1998/41,
p. 307-14.
11 Kuttan et al, J. Ethnopharmacology
1990/29, p. 35-41.
11a J. Nienhaus et al, Elemente der
Naturwissenschaft 1970/13/2, p. 45-54.
12 Hajto et al, Clinical Tri J.
1986/23/6, p. 345-58.
12a Wagner, Immunologie und
Krebskrankheit, Urachhaus, Stuttgart 1993.
13 Chernyshov et al, Complementary
Therapeutic Medecine 1997/5, p. 14-16.
14 E. M. Lukyanova et al, Forschung
Komplementärmedizin 1994/1/2, p. 58-70.
15 T. Hajto, Oncology 1986/43 (suppl. 1),
p. 51-65.
16 M. Stoss et al,
Arzneimittel-Forschung/Drug. Research 1999/49/4, p. 366-73.
17 R. W. Gorter et al, Am. J.
Therapeutics 1998/5/3, p. 18-1-7.
18 P.R. Bock, J. Hanisch, J. Hoffmann,
R.E. Dierdorf, M. Werner, Th. Schürholz en B. Schneider, Wirksamkeit und Unbedenk-
lichkeit des standardisierten Mistelextraktes Iscador® in der postoperatieven Therapie
von Patienten mit primärem Mammakarzinom: multizentrische, kontrollierte, retrolektive
Kohortenstudie, durchgeführt entsprechend den GEP-Richtlinien; Abstract.
Links
Studies naar Iscador
Bron: Altern Ther Health Med. 2001
May-Jun;7(3):57-66, 68-72, 74-6 passim.
Use of Iscador, an extract of
European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and
randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R, Kiene H, Baumgartner
SM, Ziegler R.
Institute for Preventive Medicine,
European Center for Peace and Development, United Nations, Heidelberg, Germany.
CONTEXT: In anthroposophical medicine,
total extracts of Viscum album (mistletoe) have been developed to treat cancer patients.
The oldest such product is Iscador. Although Iscador is regarded as a complementary cancer
therapy, it is the most commonly used oncological drug in Germany.
CONCLUSION: Iscador treatment can achieve
a clinically relevant prolongation of survival time of cancer patients and appears to
stimulate self-regulation.
Bron: Altern Ther Health Med. 2001
May-Jun;7(3):57-66, 68-72, 74-6 passim.
Efficacy and safety of long-term
complementary treatment with standardized European mistletoe extract (Viscum album L.) in
addition to the conventional adjuvant oncologic therapy in patients with primary
non-metastasized mammary carcinoma.
Results of a multi-center, comparative,
epidemiological cohort study in Germany and Switzerland
Bock PR, Friedel WE, Hanisch J, Karasmann
M, Schneider B.
Institut fur Angewandte
Gesundheitsforschung, IFAG Basel AG, Basel, Schweiz.
OBJECTIVES: The purpose of the study was
to evaluate the therapeutic efficacy and safety of long-term complementary therapy in
primary, non-metastatic mammary carcinoma patients in UICC stage I-III with a standardized
European mistletoe extract (Viscum album L., Iscador, "mistletoe extract") given
in addition to conventional adjuvant oncologic therapy (i.e. chemo-, radio-, and hormonal
therapy; "conventional therapy").
CONCLUSIONS: The results of the present
study confirmed the safety of the complementary therapy of patients with primary,
non-metastatic mammary carcinoma with a standardized mistletoe extract and showed
considerably fewer ADRs attributed to concurrent conventional therapy, as well as reduced
disease and treatment-associated symptoms, and suggested a prolonged overall survival in
the mistletoe extract group as compared with controls.
Bron: Arzneimittelforschung.
2004;54(8):456-66
Mistletoe treatment induces
GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil
counts: a placebo controlled randomized study in healthy subjects.
Huber R, Rostock M, Goedl R, Ludtke R,
Urech K, Buck S, Klein R.
Center for Complementary Medicine,
University Hospital Freiburg, Breisacher Str. 60, D-79106 Freiburg, Germany.
rhuber@medizin.ukl.uni-freiburg.de
OBJECTIVE: Various immunological effects
have been reported during application of mistletoe preparations. Because these data are
heterogeneous, we performed a placebo controlled study to investigate (1) effects on
peripheral granulocyte and eosinophil counts, (2) related cytokine levels and (3) whether
effects are related to mistletoe lectin (ML).
METHODS: 43 volunteers were randomized to
receive the mistletoe plant extract Iscador Quercus spezial (IQ), purified ML, IQ which
was depleted from ML, or placebo subcutaneously twice per week for 8 weeks. Weekly,
differential blood count and every four weeks spontaneous and IQ- and ML-induced cytokine
production by peripheral blood mononuclear cells (PBMC) were analyzed.
RESULTS: Leukocyte-, granulocyte-, and
eosinophil counts were significantly higher during treatment in the IQ- and ML-groups than
in the placebo group. Furthermore, a significant increase of antigen-induced production of
GM-CSF, IL-5 and IFNgamma by PBMC was observed in the IQ- and ML-group but not in the
groups receiving ML-depleted IQ or placebo. Severe side effects did not occur in any of
the subjects.
CONCLUSIONS: Treatment with IQ or ML
stimulates the production of GM-CSF, IL-5 and IFNgamma by PBMC, and this is accompanied by
an increase of eosinophil- and granulocyte-counts. These observations may, therefore, open
rational therapeutic indications for mistletoe extracts.
Bron: Eur J Med Res. 2005 Oct
18;10(10):411-8
Retrolective, comparative,
epidemiological cohort study with parallel groups design for evaluation of efficacy and
safety of drugs with "well-established use".
Bock PR, Friedel WE, Hanisch J, Karasmann
M, Schneider B.
Institute for Applied Medical Research,
IFAG Basel AG, Hohenrainweg 105, CH-4444 Rumlingen, Switzerland. paulrbock@aol.com
The randomized controlled clinical trial
(RCT) is accepted as the "golden standard" for the evaluation of efficacy and
safety of new drugs. In contrast, to demonstrate efficacy and safety of drugs with
"well-established use" that have been on the European Community market for long
time, observational comparative epidemiological studies can be used according to the
European drug regulation directive. However, because comparative epidemiological cohort
studies can share some risk of bias with other nonrandomized observational study designs,
there is a need for an approach that could effectively reduce the bias risk in this type
of studies.
STUDY OBJECTIVES: The purpose of the
study was to evaluate the therapeutic efficacy and safety of a long-term complementary
therapy of primary, non-metastatic breast carcinoma patients treated with standardized
European mistletoe extract Iscador("mistletoe") in addition to the conventional
adjuvant oncologic therapy, and compared to the control group treated with the
conventional therapy alone.
CONCLUSIONS: Complementary therapy of
patients with primary, non-metastatic breast carcinoma with the mistletoe extract Iscador
was safe and in comparison to the control group within the same study cohort showed
considerably fewer ADRs attributed to concurrent conventional therapy, reduced disease
symptoms, and suggested a significant improvement of survival. Despite some methodical
limitations that require careful study planning and conduction as well as critical
interpretation, the applied study design seems suitable to evaluate the efficacy and
safety of drugs with "well-established use", particularly in oncology. Copyright
2004 S. Karger GmbH, Freiburg
Bron: Forsch Komplementarmed Klass
Naturheilkd. 2004 Aug;11 Suppl 1:23-9.
Wil je meer onderzoeken bekijken? Ga dan
naar deze site en type Iscador in de zoekbalk
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Pager&DB=pubmed
Zet de optie display op abstract zodat je
snel de resultaten kunt lezen.
